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sensus, the assessment of a third investigator was requested. Results: Bariatric 
surgery showed to be effective and safe in reducing glycated hemoglobin levels, 
fasting blood glucose levels as well as the augmenting the chances of remission 
of type II diabetes in obese patients. ConClusions: However, the variability in 
the magnitude of the results indicated the need for new data from the 18 ongoing 
clinical trials. In other words, the technology “bariatric surgery” is efficacious as a 
whole, but there is a high variability in the treatment effect, depending of surgical 
technique.
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objeCtives: During the progressive course of type 2 diabetes mellitus (T2DM) a 
sizeable proportion of patients require insulin therapy to maintain long-term glyce-
mic control. The objective of this study was to realize a snapshot of characteristics 
and glycemic control of patients with T2DM treated by insulin in five European 
countries. Methods: T2DM patients, over 40 years old, treated by insulin (basal 
only therapy [BOT], premix, prandial or a basal-prandial free combination) ± non-
insulin antidiabetic drugs for at least 18 months, were identified in primary care 
electronic medical record databases of France, Italy, UK; Germany and Spain (IMS 
Health Longitudinal Patient Databases) during years 2013-2014. Patients’ charac-
teristics, medical history, treatment regimen, HbA1c values were retrieved and 
analyzed Results: Median age was 71.4 years in Italy (n= 7339), 70 in Germany 
(n= 3079), 67 in UK (n= 16,941), 68.2 in France (n= 3046) and 70.3 in Spain (n= 1710). 
About half of patients had a BMI ≥ 30 and hypertension was present in 69% (UK) to 
88% (Germany). A majority was treated with BOT in France (51%) and Spain (60%), 
basal-prandial in Italy (48%) and in Germany (33%), and premix insulin in UK (41%). 
BOT was the second most commonly prescribed regimen in Germany and Italy. 
Metformin was the most frequently prescribed concomitant oral antidiabetic drug. 
Mean HbA1c was 7.8% in Italy, 7.7% in Germany, 8.4% in UK, 7.9% in France and 8% 
in Spain. Overall, more than three quarter of patients (between 74% in Italy and 
83% in UK) had a HbA1c ≥ 7%, whilst 33% (Germany) to 55.5% (UK) of them had 
a HbA1c ≥ 8%. ConClusions: While regimens and patients characteristics may 
vary among countries, these results show that, despite having been treated with 
insulin for at least 18 months, a sizeable proportion of patients exhibit a suboptimal 
glycemic control.
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objeCtives: With the introduction and delisting of some glucose-lowering medi-
cations, pharmacological treatments in T2D have changed in the recent years and 
details of the current drug use patterns are not known. This descriptive study aims 
to describe characteristics of patients with type 2 diabetes and patterns of use of 
antihyperglycemic agents in France in 2013. Methods: A random sample of ≈ 
600,000 patients registered in the French national health insurances reimburse-
ment database was used. Patients with diabetes were identified through their use of 
glucose-lowering medication and coding of hospital stays and long-standing condi-
tion insurance coverage in the database. Drug utilization pattern of antihyperglyce-
mic agents were estimated considering prescriptions in Q4 2013 and compared to 
data from Q4 2007. Results: Overall 28,708 patients with T2D (estimated database 
prevalence 4.5%, 8.8% in people aged 40 and over) were identified in 2013. Mean age 
was 67.5 (SD 12.9), 54.1% were male. In Q4, 41.2% of T2D pharmacologically treated 
patients received a monotherapy, 25.6% a dual therapy, 13.7% a multi-therapy and 
19.5% an insulin therapy with or without other hypoglycemic agents. Compared to 
2007 data, a slight but significant increasing trend toward combination therapies 
and insulin was observed. The use of metformin increased over time especially in 
monotherapy (66% among monotherapy in 2013 versus 50% in 2007). All thiazolidin-
ediones and some sulfonylureas treatments were replaced by DPP-4 inhibitors and 
to a much lesser extent with GLP-1 analogues. ConClusions: Antihyperglycemic 
prescription patterns in France have changed in recent years in parallel with the 
introduction of different classes of medications to the marketplace but probably 
also in an attempt to improve glycemic control of patients. Knowledge of real life 
pattern of drug utilization remains an important dimension to better understand 
therapeutic needs in T2D management.
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objeCtives: Diabetes in the elderly is a major challenge both in terms of clinical 
management and of public health. Evidence about prescribing patterns in the elderly 
diabetic population is limited. The aim of the present study was to describe trends in 
antidiabetic drug (AD) utilization patterns in the elderly in Southern Italy with a focus 
on drugs for cardiovascular prevention and pharmaceutical costs. Methods: The 
data used for this retrospective cross-sectional study was obtained from pharmacy 
records of Caserta Local Health Authority. Subject > 65 years who received at least 
one dispensing of antidiabetic between January2010-December2014 were selected. 
be more efficacious than other GLP-1 analogues in reducing HbA1c (mean change 
-1.1%/-1.2% for liraglutide 1.2mg/1.8mg; -0.6%/-0.9% exenatide 5mcg/10mcg BID; 
-0.6% lixisenatide 20mcg). Liraglutide was superior or comparable to other GLP-1 
analogues in terms of weight, PPG, SBP, and FPG. ConClusions: Liraglutide offers 
efficacious treatment in terms of HbA1c, FPG, PPG, SBP compare to other GLP-1 
analogues and seems to offer a weight control advantage among patients on mul-
tiple OADs. The likelihood of hypoglycemic events does not appear to differ among 
GLP-1s. Our analysis was limited by the relatively small number of studies available 
and we were not able to adjust for some observed differences in patient charac-
teristics, which may have affected the evaluation. As such, the findings should be 
interpreted with some caution.
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objeCtives: To evaluate relative efficacy and safety of SGLT2i compared to DPP4i 
in patients with type 2 diabetes mellitus (T2DM) in the absence of head-to-head 
evidence. Methods: A systematic search of the literature was conducted in 
MEDLINE, EMBASE, LILACS, the Cochrane Central Register of Controlled Trials, and 
Clinicaltrials.gov to June 2015. Selected studies were randomized controlled trials 
(RCTs) that compare DPP4i plus insulin (DPP4i/INS) or SGLT2i plus insulin (SGLT2i/
INS) with placebo plus insulin (PCB/INS), as a common comparator, in patients 
with T2DM. The primary outcome was the change in HbA1c from baseline to the 
end of the intervention period. The secondary outcomes included the change in 
fasting plasma glucose, the change in body weight, and the event of hypoglyce-
mia. Covariate-adjusted indirect comparison using meta-regression analyses was 
performed. Results: We included 15 eligible RCTS comprising 6,980 patients, of 
which 9 were DPP4i studies and 5 were SGLT2i studies. Covariate-adjusted analy-
ses showed that SGLT2i/INS achieved greater reduction in HbA1c (WMD -0.24%, 
95% CI -0.43 to -0.05%) and fasting plasma glucose (WMD -18.0mg/dL, 95% CI -28.5 
to -7.6 mg/dL) with greater weight reduction (WMD -2.38 kg, 95% CI -3.18 to -1.58 
kg) than DPP4i/INS without increasing the risk of hypoglycemia (RR 1.19, 95% CI 
0.78 to 1.82). ConClusions: The addition of SGLT2i on top of pre-existing insulin 
therapy exhibits a better glycemic control and greater weight reduction than DPP4i 
in patients with inadequately controlled T2DM.
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objeCtives: Sodium-glucose transport protein 2 (SGLT-2) inhibitors demonstrate 
favorable efficacy profiles that include glycemic control and reductions in body 
weight but are associated with adverse events including ketoacidosis, urinary 
tract infections, candida vulvovaginitis, and hypoglycemia. This comparative 
safety and efficacy analysis is designed to compare relevant clinical endpoints 
in the prescribing information labels of available SGLT-2 inhibitors and identify 
the most prevalent and clinically significant outcomes which are crucial in the 
management of patients with type 2 diabetes (T2D). Methods: A multivariate 
analysis was undertaken using clinical endpoints from product information labels 
(n= 3; canaglifozin, dapagliflozin, empagliflozin) of available SGLT-2 inhibitors. 
Compounds with 24- to 26-week, placebo-controlled endpoint data were analyzed. 
Efficacy endpoints included change from baseline in hemoglobin A1c (%) and 
body weight (kg). The safety endpoints included percentage of patients reporting 
adverse events, including urinary tract infections, female genital mycotic infec-
tions, and incidence of hypoglycemic events (%). Results: No compound outper-
formed competitors in all predefined outcome measures after 24- to 26- weeks 
of treatment. Canagliflozin 300 mg + metformin reported the greatest reduction 
in body weight (-4.07 kg) and the greatest reduction in HbA1c (-1.06%). However, 
canagliflozin 300 mg + metformin (4.6%) reported the greatest incidence of hypo-
glycemia events and the greatest incidence of urinary tract infections (11.4%) 
after 26 weeks. ConClusions: Despite the robust efficacy profiles presented in 
this analysis, physicians should consider the potential adverse events associated 
with each SGLT-2 inhibitor before deciding on a treatment regimen. Diabetes treat-
ment regimens are often highly individualized, and healthcare providers must 
weigh the benefits of any treatment with its attendant risks. Of special concern 
among SGLT-2 inhibitors is the recent US FDA warning of increased risk for diabetic 
ketoacidosis associated with these compounds.
PDB12
“eFFiCACy AnD sAFety BAriAtriC surGery vs. CliniCAl treAtment in 
Control oF levels GlyCemiC AnD remission DiABetes mellitus tyPe ii 
in PAtients oBese”
Zanghelini F1, Buehler AM2, Pereira Td2
1Universidade Federal de Pernambuco, Recife, Brazil, 2Hospital Alemão oswaldo Cruz, São Paulo, 
Brazil
objeCtives: Evaluate the results on the efficacy and safety of bariatric surgery vs. 
medical treatment in remission of type 2 diabetes mellitus (T2DM) and control of 
blood glucose levels in patients with Body Mass Index ≥ 30. Methods: Following 
the methodological guidelines for the development of PTC Ministry of Health, was 
first drafted the guiding question of the study through the PICO, then a search was 
conducted in the main databases (PubMed, Embase, Cochrane, Lilacs and CRD). Each 
study recovered in the databases was selected and evaluated by two independent 
researchers, their inconsistencies resolved by consensus, when there was no con-
